Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis

doi:10.3748/wjg.v21.i14.4365

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 14

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8689)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

507

WORD

207

HTML

3757

Figures (1-3)

507

Tables (1-2)

436

Sum=5414

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1336

Download

1927

Sum=3263

Apr 14, 2015 (publication date) through Feb 19, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Meta-Analysis

World J Gastroenterol. Apr 14, 2015; 21(14): 4365-4372
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4365

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis

Qi-Bin Song, Qi Wang, Wei-Guo Hu

Qi-Bin Song, Qi Wang, Wei-Guo Hu, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China

Author contributions: Song QB, Wang Q and Hu WG contributed equally to this work; Song QB designed the research; Wang Q performed the research; Hu WG analyzed the data; Wang Q wrote the paper.

Correspondence to: Qi-Bin Song, Professor, Department of Oncology, Renmin Hospital of Wuhan University, Zhangzhidong District, Wuhan 430060, Hubei Province, China. qibinsong@163.com

Telephone: +86-27-88041911 Fax: +86-27-88041911

Received: July 20, 2014
Peer-review started: July 20, 2014
First decision: August 15, 2014
Revised: September 10, 2014
Accepted: October 15, 2014
Article in press: October 15, 2014
Published online: April 14, 2015
Processing time: 268 Days and 21.9 Hours

Core Tip

Core tip: In this study, we evaluated the correlation between Kirsten rat sarcoma viral oncogene homolog (KRAS) status and the therapeutic effects of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in patients with metastatic colorectal cancer. We focused on the relationship between KRAS status and the curative effect of anti-EGFR MoAbs in patients with metastatic colorectal cancer, and conducted a systematic meta-analysis of chemotherapy regimens, line of treatment and bevacizumab treatment. This analysis provides the first evidence that patients with wild-type KRAS metastatic colorectal cancer may not benefit from anti-EGFR MoAbs and oxaliplatin-based therapy as first-line treatment. Clinical benefit was confined to therapeutic regimens which included anti-EGFR MoAbs and fluorouracil-based therapy.